Myelofibrosis
MONDO:0044903A partial or complete replacement of the bone marrow stroma by fibrous tissue. It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003
Also known as: myelofibrosis
3203 clinical trials for this condition and its sub-types, 149 tagged with Myelofibrosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for myelofibrosis patients: experimental drug RVU120 enters Mid-Stage trial
Disease control Stopped earlyThis Phase 2 trial tests a new drug called RVU120, alone or with the standard drug ruxolitinib, in 230 adults with intermediate or high-risk myelofibrosis. The main goal is to see if the drug can shrink the spleen and improve symptoms. Participants must have not responded well to…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Rollover study offers continued itacitinib access for chronic disease patients
Disease control Stopped earlyThis study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Cord blood transplant trial for blood cancers halted early
Disease control Stopped earlyThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo for rare bone marrow cancer shows early promise, but trial halted
Disease control Stopped earlyThis study tested two experimental drugs, TQ05105 and TQB3909, taken together as tablets for people with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the combination could shrink an enlarged spleen and improve symptoms. The trial enrol…
Phase 1/2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Cancer drug trial halted early: what we know
Disease control Stopped earlyThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug P1101 tested for rare bone marrow disease
Disease control Stopped earlyThis phase 2 trial tested a drug called P1101 (a type of interferon) in 11 people with early myelofibrosis, a rare bone marrow disorder. The goal was to see if the drug could shrink the spleen, improve symptoms, or boost blood counts. The study was terminated early, so the full r…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Myelofibrosis drug combo trial ends early – what it means
Disease control Stopped earlyThis phase 3 trial tested whether adding parsaclisib to the standard drug ruxolitinib could better shrink the spleen and ease symptoms in people with myelofibrosis. The study enrolled 252 participants but was terminated early, so the full results are not available. The goal was t…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy aims to shrink spleen and ease symptoms in hard-to-treat myelofibrosis
Disease control Stopped earlyThis study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC